Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 10/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183112 | 0.89 | MME (0.50) | MMEALOX5POLB | |
| SCHEMBL9843968 | 0.84 | AOC3 (0.45) | MMEALOX5AOC3GPR88EPHX1 | |
| SCHEMBL27820666 | 0.83 | MME (0.46) | MME | |
| SCHEMBL5607432 | 0.81 | CYP2C19 (0.46) | MMEALOX5EPHX1 | |
| SCHEMBL11862111 | 0.80 | SOAT1 (0.46) | MME | |
| SCHEMBL11862095 | 0.80 | SOAT1 (0.46) | MME | |
| SCHEMBL2563024 | 0.80 | ALOX5 (0.41) | MMEALOX5EPHX1TRPM8 | |
| SCHEMBL11042231 | 0.78 | HMGCR (0.44) | MMEPOLB | |
| SCHEMBL11593762 | 0.78 | KDM4E (0.49) | — | |
| SCHEMBL20072245 | 0.78 | TAAR1 (0.49) | MMEALOX5EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | MME 44/4885ALOX5 2716/4885AOC3 3669/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | MME 44/4885ALOX5 2716/4885AOC3 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.